This year’s Verona Pharma AGM was held at 9.00 a.m. on Wednesday 2nd May 2018 at The London offices of NASDAQ, Woolgate Exchange, 25 Basinghall Street, London EC2V 5HA
For investors who are unfamiliar with the company, Verona is a clinical stage Pharmaceutical company currently focused on developing just one asset, RPL554, which has a unique mechanism of action (PDE3/PDE4 inhibition). RPL554 is currently being developed for the treatment of…
Click here for the complete AGM report if you are a full member of ShareSoc, as these reports are exclusive to our full members. The above is only an introduction to the full report, which contains much more information. Further information about access to our AGM reports can be found here.